RT Journal Article
SR Electronic
T1 Endogenous adenine is a potential driver of the cardiovascular-kidney-metabolic syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.19.24312277
DO 10.1101/2024.08.19.24312277
A1 Tamayo, Ian
A1 Lee, Hak Joo
A1 Aslam, M. Imran
A1 Liu, Jian-Jun
A1 Ragi, Nagarjunachary
A1 Karanam, Varsha
A1 Maity, Soumya
A1 Saliba, Afaf
A1 Treviño, Esmeralda
A1 Zheng, Huili
A1 Lim, Su Chi
A1 Lanzer, Jan D.
A1 Bjornstad, Petter
A1 Tuttle, Katherine
A1 Bedi, Kenneth C.
A1 Margulies, Kenneth B.
A1 Ramachandran, Vasan
A1 Abdel-Latif, Ahmed
A1 Saez-Rodriguez, Julio
A1 Iyengar, Ravi
A1 Bopassa, Jean C.
A1 Sharma, Kumar
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.19.24312277.abstract
AB Mechanisms underlying the cardiovascular-kidney-metabolic (CKM) syndrome are unknown, although key small molecule metabolites may be involved. Bulk and spatial metabolomics identified adenine to be upregulated and specifically enriched in coronary blood vessels in hearts from patients with diabetes and left ventricular hypertrophy. Single nucleus gene expression studies revealed that endothelial methylthioadenosine phosphorylase (MTAP) was increased in human hearts with hypertrophic cardiomyopathy. The urine adenine/creatinine ratio in patients was predictive of incident heart failure with preserved ejection fraction. Heart adenine and MTAP gene expression was increased in a 2-hit mouse model of hypertrophic heart disease and in a model of diastolic dysfunction with diabetes. Inhibition of MTAP blocked adenine accumulation in the heart, restored heart dysfunction in mice with type 2 diabetes and prevented ischemic heart damage in a rat model of myocardial infarction. Mechanistically, adenine-induced impaired mitophagy was reversed by reduction of mTOR. These studies indicate that endogenous adenine is in a causal pathway for heart failure and ischemic heart disease in the context of CKM syndrome.Competing Interest StatementDr. Margulies holds research grants from Amgen and serves as a scientific consultant/advisory board member for Bristol Myers Squibb and Amgen. Dr. Sharma serves on the data safety board for Cara Therapeutics and holds equity in SygnaMap. All other authors declare that they have no competing interests. Dr. Tuttle has received investigator-initiated grant support (to Providence Inland Northwest Health) from Travere and Bayer outside of the submitted work; consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk and Travere; speaker fees from AstraZeneca, Eli Lilly, and Novo Nordisk. Dr. Julia Saez-Rodriguez reports funding from GSK, Pfizer and Sanofi & fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Owkin, Pfizer and Grunenthal.Funding StatementFunding: National Institutes of Health grant UO1DK114920 (K.S.) Veteran?s Affairs Merit grant I01BX001340 (K.S.) KTPH STAR Grant 20201 (J.J.L) KTPH STAR Grant 23201 (J.J.L) Singapore National Medical Research Council Grant MOH-000066 (S.C.L) Singapore National Medical Research Council Grant MOH-000714-01 (S.C.L) Singapore National Medical Research Council Grant MOH-001327-02 (S.C.L) Federal Ministry of Education and Research Germany (BMBF) 01EJ2201B Curefib (J.D.L.) National Institutes of Health grant R01MD014712 (K.R.T.) National Institutes of Health grant U2CDK114886 (K.R.T.) National Institutes of Health grant UL1TR002319 (K.R.T.) National Institutes of Health grant U54DK083912 (K.R.T.) National Institutes of Health grant U01DK100846 (K.R.T.) National Institutes of Health grant OT2HL161847 (K.R.T.) National Institutes of Health grant UM1AI109568 (K.R.T.) Center for Disease Control project number 75D301-21-P-12254 (K.R.T) National Institutes of Health grant R01HL149891 (K.B.M) National Institutes of Health grant R01HL105993 (K.B.M) National Institutes of Health grant R01 GM137056 (RI)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Procurement of human myocardial tissue was performed under protocols and ethical regulations approved by Institutional Review Boards at the University of Pennsylvania (IRB#802781) and the Gift-of-Life Donor Program (Philadelphia, PA).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe code for the QuPath pixel classifier can be found at https://github.com/iantamayo/QuPath-Pixel-Classifier-Heart-H-E-Lipofuscin-Detection. Code for Single nuc analysis can be found at https://github.com/saezlab/adenin_in_hf. https://github.com/saezlab/adenin_in_hf https://github.com/iantamayo/QuPath-Pixel-Classifier-Heart-H-E-Lipofuscin-Detection